COAG — Hemab Therapeutics Holdings, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2114044 ·
Last close
$39.06
Market Cap
$1.83B
52W High
$55.42
52W Low
$23.00
ADV30
477,840
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -29,758,000 | -27,304,000 | 442,712,000 | 239,149,000 | 13,443,000 |
| Jun 2026 | 0 | — | -26,079,000 | -24,150,000 | 467,781,000 | 237,366,000 | 13,510,000 |
| Mar 2026 | 0 | — | -23,612,000 | -22,687,000 | 175,258,000 | 49,860,000 | 373,876,000 |
| Dec 2025 | 0 | — | -20,447,000 | -19,333,000 | 194,783,000 | 87,974,000 | 371,418,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-89,226,000
Investing CF
$-190,170,000
Financing CF
$473,556,000
CapEx
$-185,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.28
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-255,999,000
Inventory
—
Receivables
$1,205,000
ST Investments
$191,089,000
EBIT TTM
$-99,896,000
Pretax Income TTM
$-92,811,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -70,119,000 | -63,913,000 | 194,783,000 | 371,418,000 | -176,635,000 | -61,475,000 |
| Dec 2024 | 0 | -50,383,000 | -48,707,000 | 96,278,000 | 211,551,000 | -115,273,000 | -45,592,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$467,781,000
Forward EPS
$-2.65
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | $1.80B | $32.87 | — |
| REPL | Replimune Group, Inc. | $1.87B | $19.69 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $1.93B | $7.50 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.69B | $2.72 | — |
| LYCA | Lycia Therapeutics, Inc. | $1.61B | $30.92 | — |
News headlines (Yahoo Finance, 1h cache)
Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA Trial ...
2026-11-11 23:03 · Yahoo
Hemab Therapeutics to Participate in Upcoming Investor Conferences
2026-11-11 12:00 · Yahoo
Hemab (COAG) Q3 2026 Earnings Call Transcript
2026-11-10 19:31 · Yahoo
What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call
2026-11-10 15:15 · Yahoo
Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia
2026-11-09 12:00 · Yahoo
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
2026-11-04 14:05 · Yahoo
Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026
2026-11-03 12:00 · Yahoo
Hemab Therapeutics Holdings (COAG) Joins Russell Indices, Is The Stock Still Trading At A Discount?
2026-09-29 01:07 · Yahoo
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
2026-09-24 20:01 · Yahoo
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
2026-09-17 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.